CLINICAL_TRIALS
trial_result
· 2019-08-14
Clinical Trial Update: A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy [Phase 3]
Summary
A Phase 3 clinical trial evaluating rifaximin for prevention of hepatic encephalopathy reports completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bausch Health Americas, Inc. | Conditions: Hepatic Encephalopathy | Phase 3 | Status: COMPLETED | Results posted: 2019-08-14